JPMorgan raised the firm’s price target on Intuitive Surgical (ISRG) to $675 from $575 and keeps an Overweight rating on the shares. The company reported a strong close to 2024 as sales results and guidance were reiterated and profitability metrics came in better than expected, the analyst tells investors in a research note. The firm says that with strong momentum from dv5 heading into 2025 and a setup for another year of “beat-and-raise” quarters, it remains bullish on Intuitive and reiterates the stock as its top large cap pick.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Intuitive Surgical price target raised to $711 from $640 at Citi
- ISRG Earnings: Intuitive Surgical Stock Drops Despite Q4 Beat
- Intuitive Surgical Reports Strong Q4 2024 Performance
- Closing Bell Movers: Twilio up 14% on robust Investor Day outlook
- Intuitive Surgical sees FY25 procedure growth 13%-16%